Metraipolis › archive › dc_9fd3fb9dc201
Cost-Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-Line Treatment of HER2-Positive Gastric or… — Europe PMC PMID:41263467
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41263467
- DOI
- 10.1002/cam4.71379
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T20:33:24.507Z
- SHA-256 of the archived text
b6f8ecc469e3f413b7100f9e5d934a3a9bc0796d8cbede2b0a4da34b560b606c- Stable URL of this page
https://metraipolis.com/documento/dc_9fd3fb9dc201
How to cite
Cost-Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-Line Treatment of HER2-Positive Gastric or… — Europe PMC PMID:41263467 — Europe PMC (en), https://europepmc.org/article/MED/41263467 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9fd3fb9dc201 (Metraipolis archive dc_9fd3fb9dc201, sha256 b6f8ecc469e3f413b7100f9e5d934a3a9bc0796d8cbede2b0a4da34b560b606c)
BibTeX
@misc{dc9fd3fb9dc201,
title = {Cost-Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-Line Treatment of HER2-Positive Gastric or… — Europe PMC PMID:41263467},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41263467},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9fd3fb9dc201; sha256 b6f8ecc469e3f413b7100f9e5d934a3a9bc0796d8cbede2b0a4da34b560b606c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41263467. Agents can read the archived copy with the MCP tool read_document.